library. Phage display selection of FAP-specific scFv was performed on immobilized hFAP followed by selection on cells expressing murine FAP. Results: High-affinity, species-crossreactive, FAP-specific scFv were isolated upon sequential phage display selection. A bivalent derivative (minibody MO36) constructed thereof was applied for immunohistochemical analyses and allowed detection of FAP expression on stroma cells of different human carcinomas as well as on murine host stroma in a tumor xenograft model. Conclusions: MB MO36, derived from phage display selected species crossreactive scFv, is suitable for tumor stroma targeting and will be a valuable tool in the analyses of the functional role of FAP in tumor biology as well as in the evaluation of the suitability of FAP for drug targeting.
Introduction
The stroma compartment of solid tumors consists of nontransformed cell types, newly formed tumor blood vessels, and abundant stromal fibroblasts, which typically contribute 20-60% of the total tumor mass (1,2). The tumor stroma is considered to play a key role in nutrient and oxygen supply of tumors as well as in tumor invasion and metastasis (2) (3) (4) (5) (6) . Because of the tumor stroma's essential function for the tumor along with its large structural contribution, it is considered not only as a diagnostic but also as a potentially important therapeutic target.
The tumor stroma-associated antigen fibroblast activation protein (FAP) is located on stromal fibroblast of over 90% of all epithelial tumors, like breast, lung, or colon carcinomas (1). FAP is a type II transmembrane protein with serine protease activity, originally identified by the monoclonal antibody F19 (6) (7) (8) (9) .
Radiolabeled mab F19 has been successfully used for detection of colon carcinoma metastases (2) . This phase I clinical study provided evidence for the accessibility of the tumor stroma compartment via the circulation and thereby confirmed the feasibility of an antibody-mediated tumor stroma targeting concept for the treatment of solid tumors. An advantage of this approach compared to a direct targeting of the malignant cell is that stromal fibroblasts are genetically more stable than neoplastic cells. For this reason, the development of therapy resistance, caused by a loss of target antigen, seems less likely.
To study the physiologic function of FAP in vivo and its role in tumor formation and maintenance in more detail, the establishment of a murine tumor stroma model is of interest. For this purpose, the murine homologue of FAP was recently cloned and functionally characterized (10) . Murine FAP (mFAP) shares 89% amino acid identity with human FAP (hFAP) and exhibits the same structural features. Human carcinoma xenografts in immunodeficient mice revealed characteristic histologic patterns of tumor stroma and malignant epithelial cells as seen in human biopsy material, with the tumor stroma Abstract Background: Fibroblast activation protein (FAP) is a type II membrane protein expressed on tumor stroma fibroblasts in more than 90% of all carcinomas. FAP serves as a diagnostic marker and is potential therapeutic target for treatment of a wide variety of FAP ϩ carcinomas. Murine tumor stroma models and FAP-specific antibodies are required to investigate the functional role of FAP in tumor biology and its usefulness for drug targeting. We here describe the development of antibodies with crossreactivity for human (hFAP) and murine FAP (mFAP), which share 89% amino acid identity.
Material and Methods: An FAP
Ϫ/Ϫ mouse was sequentially immunized with recombinant murine and human FAP-CD8 fusion proteins. Immunoglobulin cDNA derived from hyperimmune spleen cells was used for the construction of a combinatorial single chain Fv (scFv) cells being of murine origin as confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) of mFAP expression (10) .
The existing FAP-specific reagents show no crossreactivity among different species. Therefore, our intention was to generate recombinant antibodies with crossreactivity to both hFAP and mFAP to establish murine models for evaluation of potential therapeutic reagents for human cancers. Taking advantage of the great potential of recombinant antibody technology (for review see Hayden et al. [11] , and Carter et al. [12] ), the phage display technique was chosen to isolate scFv with the desired FAP specificity. To circumvent immunologic tolerance against murine antigenic determinants, a FAP Ϫ/Ϫ mouse (13) was used for immunization with recombinant hFAP.
Materials and Methods

Construction of a Combinatorial Murine scFv Phagemid Library from FAP-Immune Mice
Spleen cells from a hyperimmunized FAP Ϫ/Ϫ mouse (13) have been used as a source for mRNA extraction. The mouse was immunized using the following schema: three immunizations with 10-30 g of a mouse CD8-hFAP complexed with the chimeric FAP-specific antibody cF19 (6), followed by two boosts of 10 g each of a mouse CD8-mFAP. A rise in serum titer was followed by enzyme-linked immunosorbent assay (ELISA). Two and a half days after the last boost, spleen cells were taken for mRNA extraction. Random hexa-nucleotid-primed cDNA synthesis was performed using the first strand synthesis kit from Roche Diagnostics, Mannheim, Germany. For PCR amplification of the Ig V-regions, a primer set based on primers previously described by Zhou et al. (14) and Dattmajumdar et al. (15) was constructed (Tables 1 and 2). PCR amplification was carried out in a total volume of 100 l containing 1-2 l of cDNA from the reverse transcription reaction mentioned above, 50 pmol of each primer, 200 M of dNTPs, 10 l of 10ϫ PCR buffer, 2 mM of MgCl 2 , and 1 U of Goldstar DNA polymerase (Eurogen-tec, Seraing, Belgium). Each variable heavy chain back primer (MHV.1-MHV.12) was combined with the forward primer MHC.F. Each light chain back primer (MKV.B1-MKV.B10) was combined with the forward primer MKC.F. The chain primer MLV.B was combined with the forward primer MLC.F. All primer pairs were used in separate reactions. For introduction of restriction sites, a second set of primers was constructed as follows: 5' of each heavy chain back primer the sequence 5'-GAATAGGCCATGGCG-3' (Nco I site underlined) and 5' of each light chain back primer the sequence 5'-TACAGGATCCACGCTA-3' (Mlu I site underlined) was added. To eliminate an internal Hind III site in MHV.B1, the following primer was used for introduction of the Nco I restriction site: 5'-GAATAGGCCATGGCGATGTGAA-GCTGCAGGAGTC-3' (Nco I site underlined). For introduction of a Hind III site, the following secondary heavy chain forward primer was used: GGCCAGTG-GATAAAGCTTTGGGGGTGTCGTTTTGGC (Hind III site underlined). 5' of the forward primers for -and -chains the sequence 5'-GACAAGCTTGCGGC-CGC-3' (Not I site underlined) was added.
The PCR reaction was performed with 25 cycles using a HYBAID thermocyler. The thermal cycle was 95ЊC for 20 sec (denaturation), 52-55ЊC for 30 sec (annealing), and 72ЊC for 30 sec (extension). For introduction of restriction sites, a second PCR reaction was performed using 10 ng of each PCR frag- (19) . The concentration of scFv in partially purified samples or crude bacterial lysates was determined by immunoblot analyses using a highly purified scFv as reference (19) .
Sandwich ELISA
Maxisorb ELISA plates (Nunc, Rochester, NY, USA) were coated with rat anti-CD8 mab o/n at 4ЊC (200 ng/well). After blocking with Roti-Block (Roth, Karlsruhe, Germany) and washing, CD8-FAP (1 g/ml) in MPBS was incubated with the immobilized ab for 1 hr at RT or o/n at 4ЊC. Serial dilution of scFv containing induced E. coli lysates in MPBS were added and incubated for 2 hr at RT. For detection, biotinylated cmyc-specific mouse mab 9E10 (Cambridge Research Biochemicals, Billingham, Cleveland, UK) was added followed by POD coupled streptavidin (Dianova, Hamburg, Germany), each incubated for 1 hr at RT. Optical density (405 nm) was measured 15-30 min after ABTS (Roche) substrate addition. For determination of functional affinity, half maximal binding concentration (EC 50 ) was calculated with the help of a hyperbolic curve fit algorithm using Sigma Plot software (Jandel Scientific, San Rafael, CA, USA).
The calculated EC 50 from the sandwich ELISA corresponded well with the affinities determined by the method of Friguet et al. (20) .
Competition ELISA for Epitope Characterization
A constant concentration (ϳ5 nM) of scFv MO33 or MO36 was mixed with various concentrations (0.2-100 nM) of cF19. The mixtures were transferred to an ELISA plate previously coated with 100 ng of CD8-hFAP per well. After incubation of 1 hr, detection of bound scFv was done with mab 9E10 followed by POD conjugated goat-anti-mouse (Dianova), each for 1 hr at RT. Optical density was measured after addition of ABTS substrate as described above. All samples were analyzed in duplicate.
Minibody Construction and Expression
An expression cassette was constructed as described by Hu et al. (21) , which encoded the following domains (5Ј-3Ј orientation): signal sequence, scFv MO36, human hinge region (IgG1), linker, human CH3 (IgG1), c-myc tag, His 6 tag. This cassette was expressed and secreted in COS 7 cells using a standard eukaryotic expression vector. The selected minibody was designated MB MO36.
Cell-Binding Assay (Cell ELISA)
For cell-binding studies, crude bacterial lysate or scFv partially purified by IMAC (22) was used. For preadsorption, 10% MPBS was added to a final concentration of 2% milk and incubated for at least 15 min at RT. The mix was clarified by centrifugation (13,000 rpm, 5 min, 2-3 times) and 3 mM of azide was added. Dilutions were made in PFA ment from the first PCR as template and primers as described above. Each primer pair was used in separate reactions and 10-12 thermal cycles. The annealing temperature for the first two cycles was 56ЊC, for the next two cycles 58ЊC, and the rest of the cycles 67ЊC. The temperature for denaturation and extension was chosen as described above.
For generation of a VH-library, the H-chains amplified in the second PCR were purified by agarose gel electrophoresis, digested with NcoI and HindIII, once more purified via an agarose gel, and ligated into the vector pSEX 81 (16) . The transformation was performed with electrocompetent Escherichia coli XL-1 blue (Stratagene, La Jolla, CA USA). The Lchains from the second PCR were purified as described above, digested with MluI and NotI, and ligated into the pSEX 81-VH-library. For transformation, electroporation was used as described. Digestion with restriction enzymes, ligation, and transformation were performed according to protocols described previously (16) .
Phage Display Selection
Phage display selection in immunotubes was essentially performed as described earlier (17) . Purified CD8-FAP fusion protein (6) 
Production and Purification of scFv
The scFv encoding regions were subcloned into the expression vector pOPE 101 (18) . The applied scFv expression cassette contained between VH and VL a linker of 18 amino acids derived from the tubulin sequence (16, 18) . Transformed E. coli JM109 were induced with 30 M of IPTG and incubated for 2-3 hr at 22-25ЊC. Harvested bacteria were sonified and clarified by centrifugation (30,000 g for 30 min). His-tagged scFv were enriched via Ni 2 ϩ -or Zn 2 ϩ -(PBS, 2% FCS, 3 mM of azide). One hundred microliters of scFv solution per well were mixed with 2-3 ϫ 10 4 cells in a v-form tissue culture plate. After an incubation of 30-40 min at RT, the cells were washed three times with ice-cold PFA (centrifugation 1500 rpm, 5 min 4ЊC). For detection, mab 9E10 in PFA and goat anti-mouse (POD conjugated) in PBS ϩ 0.1% BSA (without azide) were used. The incubation time of the detection antibodies was 30 min at RT each. Washing was performed as described above. The last washing steps were done with PBS ϩ 0.1% BSA. For the colorimetric reaction TMB (Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA substrate was added to the cells and the extinction measured at 630 nm after 15-60 min. The cell lines used for this assay were identical to those used for the phage display selection. As control for unspecific binding, the corresponding FAP-negative parental cell lines (HT1080, HEK 293) were used. Alternatively, cell binding of MB MO36 was analyzed using flow cytometry. In this case, detection of cell-bound MB MO36 was done using a FITC-labeled anti-human IgG serum (Dianova). EC 50 values were determined as described for the sandwich ELISA.
Murine Tumor Xenograft Model
Breast carcinoma cell line ZR75.1 cells (1 ϫ 10 6 ) were injected subcutaneously in the flank of a NMRI nu/nu mouse. Tumors were allowed to grow until they reached a diameter of approximately 0.5 cm. The mice were killed, and the tumors were excised, frozen, and stored at Ϫ80ЊC until use.
Immunohistochemistry
Immunohistochemical stainings were performed on freshly frozen tissue sections by the avidin-biotin complex immunoperoxidase method: 5-m thick frozen sections were cut, mounted on poly-L-lysine coated slides, air dried, and fixed in acetone (4ЊC for 10 min). Sections were treated with 0.3% H 2 O 2 for 3 min to block endogeneous peroxidase followed by blocking with normal horse or goat serum for 30 min at RT. Slides were incubated at 4ЊC with purified MB MO36 (10-20 g/ml) or negative control antibodies for 12-18 hr. Sections from mouse tissues were washed and incubated with biotinylated goat anti-human IgG (1:500, Vector Laboratories, Burlingame, CA, USA) for 30 min at room temperature, followed by avidin-biotin-horseradish peroxidase (HRP) complex (1:100 dilution). For the detection of FAP expression in human tissues, mab 9E10 (hybridoma culture supernatant, 1:5) was applied for 1 hr at RT, followed by biotinylated horse anti-mouse IgG (1:100, Vector Laboratories) and the avidin-biotin-HRP complex. The final reaction product was visualized with the chromogen DAB. Sections were counterstained with Harris' hematoxylin.
Results
Immunization of a FAP Ϫ/Ϫ Mouse With CD8-hFAP Fusion Protein
To circumvent immunologic tolerance to self-epitopes of FAP, we used a FAP Ϫ/Ϫ mouse (13) for immunization with recombinant CD8-hFAP and CD8-mFAP fusion protein.
The serum of the immunized "knock-out" mouse contained a high antibody titer (1:20,000) against hFAP as revealed by ELISA (data not shown). Even though the mouse was immunized using CD8-hFAP in an immobilized complex with the chimeric FAPspecific antibody cF19␥1, no response against this antibody could be detected. A control serum was negative for both antigens (data not shown).
Construction of a Combinatorial scFv
Splenic cDNA from the immunized mouse was used to construct a murine scFv library for phage display selection. For efficient PCR amplification of a representative murine V region repertoire, we developed a set of primers based on murine Ig primers previously described (14,15; Tables 1 and 2 ). The applied primer set comprised 11 5'-primers for amplification of the VH regions, 9 5'-primers for Vk, and 1 for Vl. The 3'-primers were annealed to the constant regions as described (23) . To avoid bias during the amplification process, each of the nondegenerated primer pairs was used in separate reactions. For each reaction, 25 PCR cycles were sufficient for an efficient amplification (data not shown). In a second PCR, restriction sites for cloning of the VH and VL regions were introduced.
In a first cloning step, a VH sublibrary was constructed (1 ϫ 10 7 independent clones). This sublibrary was randomly combined with the light chain repertoire resulting in a combinatorial library of approximately 1 ϫ 10 8 independent clones. To check for correct expression of the scFv-pIII fusion protein, randomly picked clones were induced with IPTG and analyzed in an immunoblot using the mab 10C3, which is specific for the pIII minor coat protein of the filamentous phage M13 (24) . About 80% of the analyzed clones produced fusion protein of the expected size of 116 kDa (data not shown). Diversity of the library was checked by BstNI fingerprints of PCR amplified VH and VL regions. From 14 clones checked, only 2 light chain restriction pattern were indistinguishable in a high-resolution agarose gel. All heavy chain patterns were different (data not shown).
Phage Display Selection on Immobilized CD8-hFAP Fusion Protein
The first round of panning was carried out using CD8-hFAP immobilized in immunotubes. For detection of specific binders, scFv-pIII fusion proteins were produced in E. coli in microtiter plates and subsequently an antigen-specific ELISA was performed as described previously (25) . About 25% of the H-CDR homologies could be observed, both clonesas well as mAk F19 (27)-share the joining region JH4 (28) . V ⌲ MO36 was assigned to subgroup III. V L MO33 could be identified as -chain (26) .
Binding of scFv MO33 and scFv MO36 to Human and Murine Recombinant FAP
To determine the antigen binding characteristics of the selected scFv, we developed a sandwich ELISA in which CD8-hFAP or CD8-mFAP is presented in analyzed clones bound specifically to CD8-hFAP (Fig. 1) . Sequence analyses showed that all positive clones consist of different heavy and light chains. The majority of the heavy chains belong to VH subgroup 2A (data not shown).
Selection on mFAP Positive Cells
With the intention to isolate scFv with reactivity toward both human and murine FAP, further panning rounds were performed on murine FAP. To obtain scFv with favorable specificity and affinity for cellbound mFAP and to avoid selection of scFv, which recognize denatured antigen, we established a selection strategy using a suspension of mFAP-overexpressing HEK 293 cells. After two rounds of selection on cells, the phages eluted from mFAP ϩ cells were significantly enriched in comparison to phages eluted from mFAP Ϫ control cells (Table 3 ). In the later selection round, we chose stringent selection conditions to enrich for scFv with slow off-rates. Therefore, bound phages were incubated for 2 hr in the presence of an excess of soluble CD8-hFAP at RT. The scFv clones selected with this procedure were screened for FAP-specific binders using an ELISA as described above. Seventy percent of the analyzed clones (20 of 28) showed specific binding to CD8-hFAP. BstNI-fingerprints and sequencing revealed that one clone (MO36) was predominant. However, another clone (MO33) could be identified as well.
For further analyses, the V regions of both clones were subcloned into the plasmid pOPE101 for periplasmic expression of scFv. Soluble scFv could be produced in amounts of 5-10 mg/ of E. coli culture.
Sequence Analyses of scFv MO33 and MO36
Amino acid sequences of V regions of MO33 and MO36 are shown in Figure 2 . According to Kabat et al. (26) , V H MO36 belongs to subgroup II(A) and MO33 to subgroup II(B). Although no significant 5 cells in a total volume of 1 ml). In parallel, panning was done on noncoated tubes or control cells, respectively. To determine the enrichment factor, the phage output titer from panning on antigen was divided by the output titer of the control. Percentage of binders was determined after ELISA screening using CD8-hFAP fusion protein.
#
Plates of negative control showed no colonies its native form via an immobilized rat anti-CD8 mab. Variable concentrations of scFv MO33 and scFv MO36 were incubated with this complex (Fig. 3) . The apparent affinity for CD8-hFAP and CD8-mFAP was determined for both scFv by calculation of half maximal binding concentration using a hyperbolic curve fit algorithm. For scFv MO36, the binding characteristics on murine and human FAP were nearly indistinguishable. The apparent affinity for both antigens was around 8-9 nM (Fig. 3A) . For scFv MO33, a significant difference in the apparent affinity for CD8-hFAP (5 nM) and CD8-mFAP (100 nM) was measured (Fig. 3B) . Comparable affinities could also be measured for both scFv by the method of Friguet et al. (20) using soluble CD8-hFAP as competitor (data not shown). Due to limited availability of CD8-mFAP, the latter experiment could not be performed with the murine homologue.
Binding of scFv MO33 and scFv MO36 on Cells
To study the binding characteristics on cells, a nonradioactive cell-binding assay using cells in suspension was performed (Fig. 4) . EC 50 was determined as described for the sandwich ELISA. Both scFv showed comparable binding characteristics on cell-bound FAP and on CD8-fusion protein. Again, the highest apparent affinity was revealed for scFv MO36 with an EC 50 of 1.5 nM on mFAP overexpressing cells.
Competition Studies With the FAP-Specific Chimeric mab cF19␥1
Epitope analyses of human FAP using different mab against FAP revealed that the antigenic determinant recognized by mab F19 is immunodominant (29) . In the present study, this could be confirmed using scFvs from the first panning round in a competition assay with cF19␥1. Two of five analyzed scFv from the selected panel could be competed by F19 (data not shown). Moreover, although scFv MO33 can be completely competed by cF19␥1, no competition was observed for scFv MO36 (Fig. 5) . Together, these findings suggest that the epitope recognized by scFv MO33-but not the one recognized by scFv MO36-is overlapping or at least in close proximity to the F19 epitope. However, owing to the fact that scFv MO33, but not F19, binds to mFAP, the respective epitopes cannot be entirely identical.
Construction of a Bivalent Minibody Version of scFv MO36
ScFv MO36 was also expressed as a minibody derivative (MB MO36) in mammalian cells. MB MO36 bound to mFAP-and hFAP-expressing cells, as shown by flow cytometry with a high apparent affinity (EC 50 of 1.7 nM and 3.8 nM, respectively; Fig. 6 ) and thus is a genuine species crossreactive FAP-specific reagent. Moreover, in addition to detection via the human CH3 region, the construct can be analyzed via a c-myc tag allowing immunohistochemical detection in human as well as in murine tissue.
The MB MO36 Defined Epitope Is Expressed in Human Cancer
The avidin-biotin-immunoperoxidase procedure was used to determine the distribution of the antigen recognized by MB MO36 in several human cancers including breast carcinoma (10ϫ analyzed), colorectal carcinoma (4ϫ), non-small lung carcinoma (4ϫ), ovarian carcinoma (2ϫ), kidney carcinoma (2ϫ), as well as head and neck carcinoma (2ϫ). To circumvent background staining by human immunoglobulins potentially present in the tissue, detection was performed via the myc tag. The construct showed specific staining in the stromal fibroblasts of the malignant tissues examined (Figs. 7A and 7C) . Additionally, in a xenograft model, stromal fibroblasts of murine origin induced by transplantation of a human breast carcinoma cell line could be specifically detected by MB MO36 (Fig. 7D) . Moreover, in murine embryonic tissue, subsets of primitive mesenchymal cells were stained by MB MO36 (data not shown), which is in accordance with previous immunohistochemical data on embryonal FAP expression (13) .
Discussion
In this study, we successfully used an immunized FAP Ϫ/Ϫ mouse in combination with the phage display system for generation of antibodies with crossreactivity for hFAP and mFAP. By the depletion of the mFAP gene locus in this mouse, an immunologic tolerance against epitopes shared by hFAP and mFAP could be circumvented. In a similar approach, phage display selected antibodies against murine prion proteins (PRP), using an immunized PrP Ϫ/Ϫ mouse, (30) were obtained.
In the present study, phage display selection was applied because of its advantageous features in comparison to hybridoma technology. Thus, the scFv gene cassette isolated by phage display can be used directly for the construction of recombinant antibody derivatives (11, 12, 31) . Further, in contrast to scFv cloned from hybridoma cell lines, phage display-derived scFvs are more readily produced in an active form in bacteria. For example, two FAPspecific scFvs from hybridoma, scFv F19 and scFv FB52, were expressed in E. coli XL 1 Blue in amounts of only ϳ200-300 g of soluble protein per liter of culture (B. Brocks, unpublished data), whereas phage display selected scFv MO33 and MO36 (see below) can be produced in amounts of up to 10 mg/l in the same host. This finding is in accordance with results obtained by other groups (32) . Most relevant in the present case, the selective concept of phage display appeared essential for efficient isolation of scFv with the particular feature of species crossreactivity and preferential binding to cell-bound FAP antigen, as crossreactive antibodies were only rarely obtained by conventional hybridoma technology.
However, despite these theoretical advantages, phage display does not always work with the expected efficiency, even when immunized animals have been used. For example, in an earlier study that compared antibodies derived by phage display and hybridoma technique using splenic material from identical mice, the hybridoma-derived antibodies showed larger diversity and favorable biological properties. Moreover, three to four rounds of selection were necessary in this previous study to obtain specific binders (33) .
To obtain a library that enabled us to develop efficient selection strategies, care was taken to achieve a high clonal diversity (10 8 clones) and functional expression (about 80%) of the phage display library. The general suitability of this library was apparent; 25% of the scFv clones selected in the first round of phage display were highly specific for FAP and apparently composed of independent V-region sequences, evident from a distinct restriction enzyme pattern. The applied combination strategy of sequentially immunizing and selecting with hFAP and mFAP, including the final panning on mFAPoverexpressing cells (which excluded scFvs selectively binding hFAP, denatured antigen, or epitopes only existing on the CD8-hFAP fusion protein) were likely essential steps in the successful isolation of a scFv with equal reactivity to hFAP and mFAP.
Owing to the high homology of human and murine FAP (89%) and the fact that the selection of hFAP-specific scFv was very efficient, we expected to isolate a wide range of antibodies with crossreactivity to both species in the FAP Ϫ/Ϫ mouse. However, contrary to these theoretical considerations, clone MO36 was isolated twice in two independent phage display selections and scFv MO33 was isolated only once. For this reason, we suppose that despite the FAP gene knock-out situation, only a limited antibody response against mFAP domains was elicited. A significant homology of mFAP to other structurally related murine proteins, like dipeptidyl peptidase, which shows 52% amino acid identity (10), may cause cross tolerance and thus restrict the mFAP-specific immune response.
The selected scFv MO33 and scFv MO36 showed different FAP binding characteristics. For scFv MO33 binding studies with CD8-FAP (natively immobilized in a capture ELISA) and cell membrane-bound FAP revealed affinities for hFAP in a range of 3-5 nM, whereas the affinity measured for mFAP was in a range of 100-130 nM. For this reason, it is likely that scFv MO33 originally was raised against a human epitope, which is not fully conserved on mFAP. Furthermore, competition experiments showed that the human epitope recognized by MO33 is in close vicinity or related to the immunodominant epitope of F19. In contrast to scFv MO33, the predominantly selected scFv MO36 exerts similar apparent binding affinities in the low nM range for both hFAP and mFAP, as shown by sandwich ELISA and cellbinding studies. It therefore appears likely that the epitope recognized by MO36 is highly conserved between species. Interestingly, unlike scFv MO33, scFv MO36 could not be competed by F19, suggesting that the epitope significantly differs from that recognized by F19 and MO33.
The minibody format of MO36 was suitable for immunohistochemical investigations of FAP expression in human as well as in murine tissues. This antibody format is advantageous for tumor targeting because of its bivalency, high tumor uptake, and favorable blood clearance, thereby supporting a selective accumulation in the tumor tissue (21) . The minibody derivative of scFv MO36 (MB MO36) possesses the expected high affinity and displays a greater stability as compared to the parental scFvs (data not shown). We therefore consider MB MO36 suitable for tumor stroma targeting. Thus, this re- combinant antibody will likely be a valuable tool in the analyses of the functional role of FAP in tumor biology and in the evaluation of FAP as a therapeutic target.
